1 Barouch, D. H. & Deeks, S. G. Immunologic strategies for HIV-1 remission and eradication. Science 345, 169–174 (2014)

2 Deeks, S. G. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22, 839–850 (2016)

3 Barouch, D. H. et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531–539 (2013)

4 Barouch, D. H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89–93 (2012)

5 Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997)

6 Persaud, D., Zhou, Y., Siliciano, J. M. & Siliciano, R. F. Latency in human immunodeficiency virus type 1 infection: no easy answers. J. Virol. 77, 1659–1665 (2003)

7 Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193–13197 (1997)

8 Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013)

9 Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517 (1999)

10 Chun, T. W., Davey, R. T., Jr, Engel, D., Lane, H. C. & Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874–875 (1999)

11 Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501 (2012)

12 Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381–385 (2015)

13 Liu, J. et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87–91 (2009)

14 Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74–77 (2014)

15 Abbink, P. et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654–4663 (2007)

16 Kawai, T. et al. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5, 1061–1068 (2004)

17 Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196–200 (2002)

18 Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319–327 (2014)

19 Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828–1835 (2013)

20 Banga, R. et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754–761 (2016)

21 Hel, Z. et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 6, 1140–1146 (2000)

22 Rosenberg, E. S. et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 5, e10555 (2010)

23 Li, J. Z. et al. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J. Infect. Dis. 203, 976–983 (2011)

24 Liu, J. et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J. Virol. 84, 10406–10412 (2010)

25 Burg, D., Rong, L., Neumann, A. U. & Dahari, H. Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. J. Theor. Biol. 259, 751–759 (2009)

26 Wodarz, D. et al. A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment. Philos. Trans. R. Soc. B Biol. Sci. 355, 329–343 (2000)

27 Luzyanina, T., Engelborghs, K., Ehl, S., Klenerman, P. & Bocharov, G. Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysis. Math. Biosci. 173, 1–23 (2001)

28 Althaus, C. L. & De Boer, R. J. Dynamics of immune escape during HIV/SIV infection. PLOS Comput. Biol. 4, e1000103 (2008)

29 Elemans, M. et al. Why don’t CD8+ T cells reduce the lifespan of SIV-infected cells in vivo? PLOS Comput. Biol. 7, e1002200 (2011)

30 Gadhamsetty, S., Coorens, T. & Boer, R. J. de. Notwithstanding circumstantial alibis, cytotoxic T cells can be major killers of HIV-1 infected cells. J. Virol. 306–316 (2016)

31 Chen, H. Y., Di Mascio, M., Perelson, A. S., Ho, D. D. & Zhang, L. Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc. Natl Acad. Sci. USA 104, 19079–19084 (2007)

32 De Boer, R. J., Ribeiro, R. M. & Perelson, A. S. Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLOS Comput. Biol. 6, e1000906 (2010)

33 Ramratnam, B. et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354, 1782–1785 (1999)

34 Chivers, C. MHadaptive: General Markov Chain Monte Carlo for Bayesian Inference using adaptive Metropolis-Hastings sampling. https://cran.r-project.org/web/packages/MHadaptive/MHadaptive.pdf (2012)